AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GSK Expects Upper End of Growth Targets Following Q2 Results
ByAinvest
Wednesday, Jul 30, 2025 6:21 am ET1min read
GSK reports Q2 revenue of £8bn, up 6% at constant exchange rates, driven by strong sales of specialty medicines. The company now expects annual revenue growth at the upper end of 3-5%, and growth in operating profit and core earnings per share at the upper end of 6-8%. Core operating profit rose 12% to £2.6bn, while EPS increased 15% to 46.5 pence.
GSK plc (GSK) reported its second-quarter earnings for the period ending June 30, 2025, with a notable increase in revenue and profit driven primarily by the robust performance of its specialty medicines business. The London-based pharmaceutical giant announced a revenue of £8 billion, up 6% at constant exchange rates compared to the same period last year. This figure exceeded analysts' expectations of £7.8 billion [3].The company's net profit rose to £1.44 billion from £1.17 billion in the second quarter of 2024. Core operating profit, a key metric for investors, increased by 12% to £2.63 billion, up from £2.51 billion. This growth was largely attributed to the strong performance of specialty medicines, which contributed significantly to the overall financial results [3].
GSK's earnings per share (EPS) also showed a significant improvement, increasing by 15% to 46.5 pence. This figure surpassed the average estimate of five analysts surveyed by Zacks Investment Research, which was for earnings of 39.8 pence per share [1].
The company declared a dividend of 16 pence per share for the second quarter and expects to pay out a total of 64 pence for the full year. GSK has a history of beating earnings estimates, having done so 100% of the time over the last two years [2].
Looking ahead, GSK is optimistic about its full-year prospects. The company expects annual revenue growth to be at the upper end of its previously provided range of 3% to 5%. Additionally, it anticipates growth in core operating profit toward the upper end of its range of between 6% and 8% [3].
References:
[1] https://finance.yahoo.com/news/glaxo-q2-earnings-snapshot-090346408.html
[2] https://seekingalpha.com/news/4473401-gsk-q2-2025-earnings-preview
[3] https://www.tradingview.com/news/DJN_DN20250730002307:0-gsk-upbeat-on-guidance-after-specialty-medicines-boost-sales/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet